CYPRESS - CYPHER for Evaluating Sustained Safety

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Cordis Corporation
ClinicalTrials.gov Identifier:
NCT00954707
First received: August 6, 2009
Last updated: January 13, 2014
Last verified: January 2014
  Purpose

CYPRESS: A Prospective,Randomized,Multi-Center,Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHER® Sirolimus-eluting Coronary Stent (CYPHER® Stent)


Condition Intervention Phase
Coronary Artery Disease
Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin
Drug: Placebo & Aspirin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Multi-Center, Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention With the CYPHER® Sirolimus-eluting Coronary Stent (CYPHER® Stent)

Resource links provided by NLM:


Further study details as provided by Cordis Corporation:

Primary Outcome Measures:
  • Phase I: the Rate of Target Lesion Failure (TLF) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Target lesion failure (TLF) is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months.


Secondary Outcome Measures:
  • Rate of Device Success [ Time Frame: From post- procedure to hospital discharge, up to 39 days ] [ Designated as safety issue: No ]
    A study device success is defined as achievement of a final residual diameter stenosis of < 50% (by QCA), using the assigned device only. If QCA is not available, the visual estimate of diameter stenosis is used.

  • Rate of Lesion Success [ Time Frame: From post- procedure to hospital discharge, up to 39 days ] [ Designated as safety issue: Yes ]
    Lesion success is defined as the attainment of < 50% residual stenosis (by Quantitative coronary angiography (QCA)) using any percutaneous method.

  • Rate of Procedure Success [ Time Frame: From post- procedure to hospital discharge, up to 39 days ] [ Designated as safety issue: No ]
    Procedure success is defined as the achievement of a final diameter stenosis of < 50% (by QCA) using any percutaneous method, without the occurrence of death, Myocardial infarction (MI), or repeat coronary revascularization of the target lesion during the hospital stay.

  • Rate of Clinically-driven Target Lesion Revascularization (TVR) [ Time Frame: 12 Months ] [ Designated as safety issue: Yes ]
    Defined as any "clinically-driven" repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel. Clinically-driven revascularizations are those in which the subject has a positive functional study, ischemic ECG changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis ≥50% by QCA.

  • Rate of Clinically Driven Target Vessel Revascularization (TVR) [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Defined as any clinically driven repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel. Clinically-driven revascularizations are those in which the subject has a positive functional study, ischemic ECG changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis ≥50% by QCA.

  • Rate of Target Vessel Failure (TVF) [ Time Frame: 12 Months ] [ Designated as safety issue: Yes ]
    Defined as target vessel revascularization, recurrent infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel.

  • Rate of Major Adverse Cardiac Events (MACE) [ Time Frame: 12 Months ] [ Designated as safety issue: Yes ]
    MACE includes Death, myocardial infarction, emergent bypass surgery, or target lesion revascularization at 12 months

  • Rate of Protocol Defined Stent Thrombosis (ST) [ Time Frame: 12 Months ] [ Designated as safety issue: Yes ]
    Protocol defined ST includes early and late ST. Early thrombosis is defined as composite thirty-day ischemic endpoint including death, Q-wave myocardial infarction, or subabrupt closure requiring revascularization. Late thrombosis is defined as myocardial infarction occurring > 30 days after the index procedure and attributable to the target vessel with angiographic documentation (site reported or by qualitative coronary angiography) of thrombus or total occlusion at the target site and freedom from an interim revascularization of the target vessel.

  • Rate of Academic Research Consortium (ARC) Defined Stent Thrombosis (ST) [ Time Frame: 12 Months ] [ Designated as safety issue: Yes ]
    ARC defined ST classifies ST by type - definite, probable, possible; by timing - acute, sub-acute, late, very late. Definite includes angiographic or pathologic confirmation; probable includes Any unexplained death within the first 30 days or Any MI (related to documented acute ischemia and without another obvious cause) in the territory of the stent; Possible includes Any unexplained death > 30 days. Acute includes those ≤ 24 hours post procedure; sub-acute includes those > 24 hours to ≤ 30 days post procedure; and late includes those > 30 days to ≤ 1 year post procedure; and very late includes those > 1 year post procedure.

  • Rate of Protocol Defined Major Bleeding Complications [ Time Frame: 12 Months ] [ Designated as safety issue: Yes ]
    Defined by the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) classification, including severe and moderate bleeding combined.

  • Rate of Cardiac Death [ Time Frame: 12 Months ] [ Designated as safety issue: Yes ]
    Include all deaths due to cardiac causes.

  • Rate of Non-cardiac Death [ Time Frame: 12 Months ] [ Designated as safety issue: Yes ]
    Include all deaths due to non-cardiac causes.


Enrollment: 2509
Study Start Date: August 2009
Estimated Study Completion Date: March 2016
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 12m DAPT Group Drug: Placebo & Aspirin
This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
Active Comparator: 30m DAPT Group Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin
This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of thienopyridine treatment in addition to aspirin.

Detailed Description:

During Phase I (non-randomized phase) of this study, the primary objective is to assess the rate of target lesion failure in subjects implanted with the CYPHER® stent and receiving dual antiplatelet therapy for 12 months.

During Phase II (randomized phase) of this study, the primary objective is to assess safety (major and minor bleeding), MACCE, and ST rates in subjects treated with dual antiplatelet therapy for 12 or 30 months following CYPHER® stent implantation.

*Subjects treated with the CYPHER® 2.25mm stent will be followed through 60 months.

**The last 500 patients enrolled will not be eligible for randomization.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DAPT Group - Inclusion Criteria:

Phase I: Enrollment Inclusion Criteria

Subjects must meet ALL of the following inclusion criteria to be enrolled in the study:

  • The subject must be 18 years of age.
  • Subjects undergoing percutaneous intervention with stent deployment
  • Subjects without known contraindication to dual antiplatelet therapy for at least 30 months after enrollment and stent implantation.
  • The subject or Legally Authorized Representative has consented to participate and has authorized the collection and release of his/her medical information by signing the "Patient Informed Consent Form" that is approved by the Institutional Review Board or Independent Ethics Committee. The informed consent will be valid for the duration of the trial or until the subject withdraws.

DAPT Group Phase II: Randomization Inclusion Criterion at 12 months

Subjects must meet the following criterion to be eligible for randomization in the study:

  • Subject is 12 Month Clear

DAPT Group - Exclusion Criteria:

Phase I: Enrollment Exclusion Criteria

Subjects will be excluded if ANY of the following exclusion criteria apply:

  • Index procedure requiring use of a stent with a nominal diameter < 2.25 mm or > 3.5 mm.
  • Pregnant women.
  • Planned (at time of enrollment) surgery necessitating discontinuation of antiplatelet therapy within the 30 months following enrollment.
  • Current medical condition with a life expectancy of less than 3 years.
  • Concurrent enrollment in another device or drug study where the primary endpoint has not been reached or the device/drug might affect major endpoint outcomes in either Phase I or Phase II of the study.
  • The subject may only be enrolled in the study once.
  • Subjects on warfarin or similar anticoagulant therapy.
  • Subjects with hypersensitivity or allergies to one of the drugs or components indicated in the Instructions for Use for the device implanted.
  • Subjects unable to give informed consent.
  • Subject treated with both DES and BMS during the index procedure.

DAPT Group Phase II: Randomization Exclusion Criteria at 12 months

Subjects will be excluded from randomization if any of the following criteria are met:

  • Pregnant women.
  • Subject switched thienopyridine type within 6 months prior to randomization
  • Percutaneous coronary interventions or cardiac surgery between 6 weeks post index procedure and randomization.
  • Planned surgery necessitating discontinuation of antiplatelet therapy within the 21 months following randomization.
  • Current medical condition with a life expectancy of less than 3 years.
  • Subjects on subsequent warfarin or similar anticoagulant therapy.
  • Subjects who do not receive any CYPHER® Stent during the index procedure.

Non-DAPT Group

The following inclusion and exclusion criteria are for the Non-DAPT subjects. These criteria will be used to determine if the subject meets the near on-label definition

Non-DAPT Group - Inclusion Criteria:

Subjects must meet ALL of the following criteria to be enrolled in this study:

  1. The subject must be ≥18 years of age
  2. Index procedure requiring use of a stent with a nominal diameter 2.25mm to 3.5mm
  3. Lesion Length ≤ 34mm
  4. Up to 2 lesions in up to 2 vessels (2 in one vessel or 1 in each of 2 vessels)
  5. Ejection fraction > 30%
  6. Target lesion stenosis is >50% and <100% (visual estimate)
  7. Female of childbearing potential must have a negative pregnancy test within 10 days prior to enrollment
  8. The subject or Legally Authorized Representative has consented to participate and has authorized the collection and release of his/her medical information by signing the "Patient Informed Consent Form"

Non-DAPT Group - Exclusion criteria

And must NOT meet any of the following exclusion criteria:

  1. Target Lesion includes Bifurcations with side branch diameter >2.5mm
  2. Patient with excessive calcified/angulated lesion that is not suitable for stenting in the Investigator's opinion
  3. Restenotic Target Lesion previously treated with a stent
  4. Greater than 2 overlapping stents used to treat target lesion.
  5. Target Lesion within an unprotected Left Main (LM) with ≥50% stenosis
  6. Target Lesion within a coronary bypass graft (e.g., saphenous vein or arterial graft)
  7. Chronic (> 3 months) Total Occlusion (CTO) Lesions, TIMI grade 0 or 1 in the target lesion
  8. ST segment Elevation Myocardial Infarction (STEMI) within 30 days or non-STEMI within 72 hours
  9. Renal insufficiency (creatinine >2.5 mg) or dialysis dependent
  10. Lesion with visible clot
  11. Patient with prior brachytherapy
  12. Documented left ventricular ejection fraction is ≤30%
  13. Pretreatment with devices other than conventional balloon angioplasty
  14. Recipient of heart transplant
  15. Subject with a life expectancy less than 1 year
  16. Known allergies to the following: aspirin, all commercially available anti-platelet drugs heparin, stainless steel, contrast agent (that cannot be managed medically), or sirolimus (that cannot be managed medically);
  17. Any significant medical condition which, in the Investigator's opinion, may interfere with the subject's optimal participation in the study;
  18. Currently participating in an investigational drug or device study that has either not completed the primary endpoint where the prior study drug/device might affect this study's primary endpoint
  19. In the Investigator's opinion, the lesion is not suitable for stenting.
  20. Known bleeding or hypercoagulable disorder;
  21. Known or suspected active infection at the time of the study procedures;
  22. Subject is known to be pregnant
  23. Subject is a prisoner, mentally incompetent, and/or alcohol or drug abuser;
  24. Planned (at the time of enrollment) surgery necessitating discontinuation of anti-platelet therapy within the twelve (12) months following enrollment.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00954707

Locations
United States, Ohio
University Hospitals, Case Medical Center (Cleveland)
Cleveland, Ohio, United States, 44106
Sponsors and Collaborators
Cordis Corporation
Investigators
Principal Investigator: Daniel Simon, M.D. University Hospitals, Case Medical Center (Cleveland)
Principal Investigator: David Kandzari, M.D. Piedmont Hospital, Atlanta, GA
  More Information

No publications provided

Responsible Party: Cordis Corporation
ClinicalTrials.gov Identifier: NCT00954707     History of Changes
Other Study ID Numbers: P09-6301
Study First Received: August 6, 2009
Results First Received: April 26, 2013
Last Updated: January 13, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Cordis Corporation:
Atherosclerosis

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Aspirin
Clopidogrel
Prasugrel
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents
Hematologic Agents
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics

ClinicalTrials.gov processed this record on April 14, 2014